Intellia Therapeutics and Sarepta Therapeutics have faced setbacks impacting their treatments, leading to a decline in market value. Investing in these biotechs is considered risky due to uncertainties. Gene-editing medicines offer benefits but also pose challenges, like manufacturing and side effects.

Intellia Therapeutics focuses on gene editing for diseases with few treatment options. However, a patient death led to a pause in clinical trials for one of its candidates. Regulators may lift the hold, but risks remain. Sarepta Therapeutics also experienced patient deaths, affecting its stock price and revenue.

Both Intellia and Sarepta are facing challenges due to patient deaths related to their treatments, impacting their financial performance. The risks associated with investing in these biotechs are high, making them unattractive options for investors. Consider other stocks with better potential for returns in the market.

Read more at Yahoo Finance: 2 Beaten-Down Stocks to Avoid Right Now